Doebele Robert 4

What Happened

• Robert Doebele, Chief Medical Officer of Boundless Bio, was granted a derivative equity award for 230,000 shares on 2026-01-23. The reported acquisition price was $0.00 (no cash paid), so the immediate reported value is $0 on the Form 4; the award is a derivative equity grant (e.g., stock option/RSU-type award) rather than an open-market purchase or sale.

Key Details

• Transaction date: January 23, 2026; Form 4 filed January 26, 2026 (filing appears timely).
• Price: $0.00 per share; reported total consideration $0 (derivative award).
• Vesting: Commencement date January 1, 2026; vests in 48 substantially equal monthly installments — 1/48th vests on February 1, 2026, and monthly thereafter.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: Vesting schedule described above (monthly over 48 months).
• No 10b5-1 plan, tax-withholding, or sale/exercise details were reported in the provided filing.

Context

• This was an equity award grant (derivative), not a cash purchase or sale; such awards are common for executive compensation and do not by themselves indicate buying or selling sentiment. The monthly vesting schedule means the executive will gain a small portion of vested shares each month over four years, subject to continued service and any plan terms.